India’s anti-obesity drug market is slowing after a semaglutide-led boom, as generic sales growth moderated following the initial surge triggered by lower-cost alternatives.
India is preparing a major policy initiative aimed at boosting domestic pharmaceutical innovation, with the government working on a new scheme focused on the bulk drug research ecosystem. The proposed initiative is expected to strengthen...
Next-generation obesity drugs are evolving beyond weight loss to target sleep apnea, diabetes, and joint pain, signaling a shift toward multi-disease therapies in the global pharma market.
Alembic Pharma announced its participation in a newly incorporated Canadian company focused on developing, commercializing, distributing, and marketing pharmaceutical products in Canada. The move marks another step in the company's international...
Indian pharma companies could soon find a new growth destination in Central Asia as Uzbekistan intensifies efforts to attract foreign investment in its pharmaceutical sector. The country has signaled its willingness to offer additional incentives...
The Central Drugs Standard Control Organisation (CDSCO) has flagged several drug samples linked to some of India’s leading pharmaceutical companies as Not of Standard Quality (NSQ) for April 2026, highlighting ongoing concerns around drug quali...
.jpeg "NPPA May Approve Price Hike for Key Cancer Drugs Amid Cost Surge")
NPPA may approve price hike for cancer drugs like carboplatin and cisplatin as raw material costs surge, raising supply concerns and impacting oncology treatment access in India.
Explore how myths around blood cancer are debunked with facts on CAR T-cell therapy, early detection, and advanced treatment options improving survival and patient outcomes.
Alembic Pharma gets USFDA approval for Haloperidol Tablets across multiple strengths, strengthening its US generics portfolio in CNS segment with continued regulatory momentum.
Mumbai-based pharmaceutical company Lupin Limited has received U.S. FDA approval for Ranluspec biosimilar (ranibizumab-hkdz), a biosimilar to Lucentis used in the treatment of serious eye conditions. The approval marks an important step in Lupin...
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")